Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NRAS | P01111 | 5/20 | 0.45 |
| ▸ | FLT3 | P36888 | 5/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.30 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.30 |
| ▸ | FYN | P06241 | 2/20 | 0.30 |
| ▸ | LCK | P06239 | 1/20 | 0.30 |
| ▸ | RET | P07949 | 1/20 | 0.30 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.30 |
| ▸ | CDK7 | P50613 | 1/20 | 0.30 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.30 |
| ▸ | CCNH | P51946 | 1/20 | 0.30 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27331195 | 1.00 | NRAS (0.45) | NRASFLT3CYP3A4KCNH2TLR8 | |
| SCHEMBL27329633 | 0.97 | NRAS (0.44) | NRASFLT3 | |
| SCHEMBL31739911 | 0.97 | NRAS (0.44) | NRASFLT3 | |
| SCHEMBL31739941 | 0.97 | NRAS (0.44) | NRASFLT3 | |
| SCHEMBL27326957 | 0.97 | NRAS (0.44) | NRASFLT3 | |
| SCHEMBL27327088 | 0.97 | NRAS (0.44) | NRASFLT3 | |
| SCHEMBL27329557 | 0.97 | NRAS (0.44) | NRASFLT3 | |
| SCHEMBL31739826 | 0.96 | NRAS (0.44) | NRASFLT3 | |
| SCHEMBL27329565 | 0.96 | NRAS (0.44) | NRASFLT3 | |
| SCHEMBL27327079 | 0.96 | NRAS (0.44) | NRASFLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12534469-B2 | Multi-cyclic IRAK and FLT3 inhibiting compounds and uses thereof | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2026-01-27 | — | — | US | disclosed |
| US-20250368648-A1 | MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2025-12-04 | — | — | US | disclosed |
| US-20240124468-A1 | MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF | CHILDREN'S HOSPITAL MEDICAL CENTER | 2024-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240124468-A1 | MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF | FLT3, IRAK1, IRAK2 | NRAS 372/4885FLT3 1/4885CYP3A4 4442/4885 |
| US-20250368648-A1 | MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF | FLT3, IRAK1, IRAK2 | NRAS 371/4885FLT3 1/4885CYP3A4 4434/4885 |
| US-12534469-B2 | Multi-cyclic IRAK and FLT3 inhibiting compounds and uses thereof | FLT3, IRAK3, IRAK2 | NRAS 277/4885FLT3 1/4885CYP3A4 3302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.